来那度胺高剂量和低剂量地塞米松.pdfVIP

Articles Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial S Vincent Rajkumar, Susanna Jacobus, Natalie S Callander, Rafael Fonseca, David H Vesole, Michael E Williams, Rafat Abonour, David S Siegel, Michael Katz, Philip R Greipp, for the Eastern Cooperative Oncology Group Summary Background High-dose dexamethasone is a mainstay of therapy for multiple myeloma. We studied whether low-dose Lancet Oncol 2010; 11: 29–37 dexamethasone in combination with lenalidomide is non-inferior to and has lower toxicity than high-dose Published Online dexamethasone plus lenalidomide. October 22, 2009 DOI:10.1016/S1470- 2045(09)70284-0 Methods Patients with untreated symptomatic myeloma were randomly assigned in this open-label non-inferiority See Refl ection and Reaction trial to lenalidomide 25 mg on days 1–21 plus dexamethasone 40 mg on days 1–4, 9–12, and 17–20 of a 28-day cycle page 3 (high dose), or lenalidomide given on the same schedule with dexamethasone 40 m